Garrison Bradford & Associates Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,950 shares of the medical research company’s stock after selling 2,703 shares during the quarter. Thermo Fisher Scientific accounts for approximately 3.3% of Garrison Bradford & Associates Inc.’s holdings, making the stock its 9th biggest holding. Garrison Bradford & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $3,978,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of Thermo Fisher Scientific by 57.0% in the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares in the last quarter. Americafirst Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $876,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after purchasing an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $1,451,000. 86.25% of the stock is currently owned by hedge funds and other institutional investors.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the transaction, the chief executive officer now owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Inc. (TMO) traded up $1.10 during midday trading on Friday, reaching $213.51. The company had a trading volume of 1,418,994 shares, compared to its average volume of 1,577,492. Thermo Fisher Scientific Inc. has a twelve month low of $140.00 and a twelve month high of $214.57. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The company has a market cap of $85,170.00, a PE ratio of 36.25, a price-to-earnings-growth ratio of 1.72 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same period in the prior year, the business earned $2.03 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, January 15th. Shareholders of record on Friday, December 15th were given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.
Several equities research analysts have recently commented on the stock. Jefferies Group restated a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann restated an “outperform” rating and issued a $200.00 target price (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 target price on the stock. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $212.21.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.